These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6687766)

  • 21. Methodological assessment and applications of a radioimmunoassay for thromboxane (TxB2) to measurement of TxB2 release by platelets.
    Giannessi D; De Caterina R; Gazzetti P; Bernini W; Masini S; Zucchelli GC
    J Nucl Med Allied Sci; 1982; 26(1):25-33. PubMed ID: 7108634
    [No Abstract]   [Full Text] [Related]  

  • 22. Normal plasma thromboxane B2 (TXB2) and 6-keto-PGF1 alpha levels in childhood diabetes.
    Orlandi M; Davì G; Triolo G; Tomasi V; Strano A
    Prostaglandins Leukot Med; 1983 Dec; 12(4):437-8. PubMed ID: 6583712
    [No Abstract]   [Full Text] [Related]  

  • 23. [Changes of platelet aggregation, serum thromboxane and prostacyclin in lung cancer and pulmonary metastatic patients following operation].
    Takeda H; Kashimura Y; Takeoka T; Hashimoto M; Tanabe T
    Kyobu Geka; 1984 Sep; 37(10):773-7. PubMed ID: 6389949
    [No Abstract]   [Full Text] [Related]  

  • 24. Dose-dependent stimulation of renal prostaglandin synthesis by deamino-8-D-arginine vasopressin in rats with hereditary diabetes insipidus.
    Walker LA; Frölich JC
    J Pharmacol Exp Ther; 1981 Apr; 217(1):87-91. PubMed ID: 7205662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of DDAVP on plasma renin activity in man.
    Radó JP; Boer P
    Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):307-10. PubMed ID: 489197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Raised plasma levels of thromboxane B2 in systemic mastocytosis.
    Ouwendijk RJ; Zijlstra FJ; Wilson JH; Bonta IL; Vincent JE; Stolz E
    Eur J Clin Invest; 1983 Jun; 13(3):227-9. PubMed ID: 6409646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal prostaglandin efflux induced by vasopressin, dDAVP and arachidonic acid: contrasting profile and sites of release.
    Miller MJ; Westlin WF; McNeill H; McGiff JC
    Clin Exp Pharmacol Physiol; 1986 Aug; 13(8):577-84. PubMed ID: 3791710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of hypoxemia and pulmonary thromboembolism on plasma levels of 6-keto PGF 1 alpha, TxB, histamine and serotonin in anesthetized dogs (author's transl)].
    Ishihara Y; Kitamura S; Kosaka K; Harasawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1981 Aug; 19(8):542-8. PubMed ID: 6895531
    [No Abstract]   [Full Text] [Related]  

  • 29. Thromboxane and 6-oxo-PGF1 alpha in the plasma of patients with diabetes type I and II.
    Rösen P; Hohl C; Tschöpe D; Körner A; Halfmann U; Berger M
    Prog Clin Biol Res; 1987; 242():247-52. PubMed ID: 3671386
    [No Abstract]   [Full Text] [Related]  

  • 30. Interaction between a synthetic analogue of vasopressin and human peripheral blood lymphocytes.
    Wickramasinghe SN; Valdimarsson H; Williams B
    J Clin Lab Immunol; 1982 Jan; 7(1):67-70. PubMed ID: 6279851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of thromboxane formation prevents endotoxin-induced renal fibrin deposition in jaundiced rats.
    Westwick J; Fletcher MS; Kakkar VV
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():83-91. PubMed ID: 6221642
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanism of vasopressin-induced platelet aggregation.
    Filep J; Rosenkranz B
    Thromb Res; 1987 Jan; 45(1):7-15. PubMed ID: 3105115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds.
    Gerrard JM; Singhroy S; Duta E; Nosek-Cenkowska B; Israels SJ; Israels ED
    Thromb Res; 1990 Oct; 60(1):79-85. PubMed ID: 2278038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocorticoids do not decrease thromboxane and prostacyclin levels in human blood.
    Puustinen T; Dahl ML; Uotila P; Haataja M
    Prostaglandins Leukot Med; 1984 Sep; 15(3):409-10. PubMed ID: 6387721
    [No Abstract]   [Full Text] [Related]  

  • 35. [Biochemistry of coronary artery disease--prostaglandins].
    Tada M; Kuzuya T; Ohmori M
    Rinsho Byori; 1983 Aug; 31(8):854-9. PubMed ID: 6361336
    [No Abstract]   [Full Text] [Related]  

  • 36. Platelet-activating factor secreted by DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells.
    Hashemi S; Palmer DS; Aye MT; Ganz PR
    J Cell Physiol; 1993 Mar; 154(3):496-505. PubMed ID: 8436598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) in normal individuals (author's transl)].
    Takahashi H; Itoh M; Kobayashi I; Hattori A; Takahashi K; Sakuragawa N; Shibata A; Tsukada T
    Nihon Ketsueki Gakkai Zasshi; 1980 Oct; 43(5):907-17. PubMed ID: 6785953
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes in thromboxane formation by platelets during and after a continuous endotoxin infusion into rabbits.
    Ditter H; Matthias FR
    Vasa; 1984; 13(4):327-32. PubMed ID: 6516562
    [No Abstract]   [Full Text] [Related]  

  • 39. [Experiences with intranasal and parenteral use of 1-desamino-8-D-arginine vasopressin (DDAVP). Use in a simple test of renal concentrating ability].
    Tuschy U; Szeszat S; Rindfleisch U
    Z Gesamte Inn Med; 1984 Jun; 39(11):265-8. PubMed ID: 6475171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
    Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.